

**To resect or not?
Is it possible to get the balance right?**

M. Liberda
Dept. of gastroenterology/endoscopy
Valasske Mezirici Hospital
Czech Republic




D. De Looze
Dept. of gastroenterology/endoscopy
University Hospital Gent
Belgium





Case – medical background

- 73 year old male (january 2015)
- Personal History:
Arterial Hypertension (WHO grade III)
Obesity (BMI 34) and hypercholesterolaemia
COPD and ex-smoker (stop 5 months, >30 packyears)
Coronary Artery Disease
August 2014 myocardial infarction with ventricular fibrillation, CPR, pneumonia, respiratory failure
August 2014 percutaneous coronary intervention with DES (drug eluting stent) placement.
- Medication: aspirin 100mg/d, clopidogrel 75mg/d (Plavix®), atorvastatin 20mg/d, metoprolol 25mg/d, furosemide 40mg/d, omeprazole 20mg/d, theophylline 300mg bid, allopurinol 100mg/d









Case – presentation

January 2015 + iFOBT (no complaints, GP driven iFOBT)

In what circumstances would you do a colonoscopy at this moment with regard to the dual antiplatelet aggregation regimen?

1. Postpone the colonoscopy until august 2015 (presumed stop clopidogrel after DES).
2. Both aspirin and clopidogrel withdrawal (5 days)
3. Clopidogrel withdrawal (5d), maintain aspirin
4. Continue dual APA (aspirin+ , clopidogrel +)






 *ESGE guidelines. Endoscopy 2011; 43:445-458*

Bleeding risk	Endoscopic procedure	Continuation of aspirin?	Continuation of clopidogrel or prasugrel?
Low risk	EGD and colonoscopy +/- biopsy	Yes	Yes
	EUS without FNA	Yes	Yes
	Colonic polypectomy < 1 cm	Yes	No*
	Dilation of digestive stenoses	Yes	No
	EUS-FNA of solid masses	Yes	No
	Digestive stenting	Yes	No
	ERCP with stent placement or papillary balloon dilation without endoscopic sphincterotomy	Yes	Yes
	Argon plasma coagulation	Yes	No†
	FMR, FSD and ampullary resection	No	No
	Endoscopic sphincterotomy	Yes	No
High risk	Endoscopic sphincterotomy + large-balloon papillary dilation	No	No
	Colonic polypectomy > 1 cm	Yes	No*
	EUS-FNA of cystic lesions	No	No
	Percutaneous endoscopic gastrostomy	Yes	n.a.
	Esophageal variceal band ligation	Yes	No

Case – colonoscopy 1/2015

- Continuation of aspirin and clopidogrel
- 8 polyps + flat lesions (≤ 1 cm) were removed by snare polypectomy and submucosal lifting (EMR)
- 2 large semipedunculated polyps size (> 2 cm) were not resected at this moment (Pit pattern IV)




ESGE guidelines. Endoscopy 2011; 43:445-458

Bleeding risk	Endoscopic procedure	Continuation of aspirin?	Continuation of clopidogrel or prasugrel?
Low risk	EGD and colonoscopy +/- biopsy	Yes	Yes
	EUS without FNA	Yes	Yes
	Colonic polypectomy ≤ 1 cm	Yes	No*
	Dilation of digestive stenoses	Yes	No
	EUS-FNA of solid masses	Yes	No
	Digestive stenting	Yes	No
High risk	ERC† with stent placement or papillary balloon dilation without endoscopic sphincterotomy	Yes	Yes
	Argon plasma coagulation	Yes	No†
	EMR, ESD and ampullary resection	No	No
	Endoscopic sphincterotomy	Yes	No
	Endoscopic sphincterotomy + large-balloon papillary dilation	No	No
	Colonic polypectomy > 1 cm	Yes	No*
	EUS-FNA of cystic lesions	No	No
	Percutaneous endoscopic gastrostomy	Yes	n.a.
Esophageal variceal band ligation	Yes	No	

Data for statement 2015 :

- All recent studies have confirmed that overall PPB risk is not increased in patients taking low dose aspirin.
- Recent studies have showed that the risk of postpolypectomy bleeding in patients taking clopidogrel is increased both for overall and delayed bleeding



How to treat the large, semipedunculated (> 2 cm) type IV, polyps?

1. Postpone endoscopic polypectomy until august 2015 (presumed stop clopidogrel after DES).
2. Clopidogrel withdrawal (5d), maintain aspirin
3. Continue dual APA (aspirin+ , clopidogrel +)
4. Continue dual APA + close polypectomy defect




RISK of severe thrombo-embolic event when stopping APA

HIGH: DES < 12 months

RISK of postpolypectomy bleeding, if not stopping APA

Overall risk (no APA): 1,2%
Post-EMR bleeding: 3-7%

Risk \uparrow Clopidogrel > 1 cm polyps



RISK of the lesion

Progression adenoma to invasive cancer is slow

NBI International Colorectal Endoscopic (NICE) Classification*			
	Type 1	Type 2	Type 3
Color	Same or lighter than background	Brownier relative to background (softly color arises from vessels)	Brown to dark brown relative to background; sometimes patchy whitish areas
Vessels	None, or isolated tiny vessels clearing across the lesion	Brown vessels surrounding white structures**	Has areas of disrupted or missing vessels
Surface Pattern	Dark or white spots of uniform size, or homogenous absence of pattern	Oval, tubular or branched white structure surrounded by brown vessels**	Amorphous or absent surface pattern
Most likely pathology	Hyperplastic	Adenoma***	Deep submucosal invasive cancer
Examples			

* Can be applied using colonoscopes with or without optical zoom/magnification.
 ** These structures regular or irregular may represent the pits and the crypts of the crypt opening.
 *** Type 2 consists of Vienna classification types 1, 4 and superficial 1 left adenomas with either low or high grade dysplasia, or with superficial submucosal carcinomas. The presence of high grade dysplasia or superficial submucosal carcinoma may be supported by an irregular vessel or surface pattern, and is often associated with atypical morphology (e.g., ulcerated area).

Traditional adenoma-carcinoma pathway

Only 1 in 20 adenomas will develop in cancer
Slow progression: 10-15 years

RISK of severe thrombo-embolic event when stopping APA
HIGH: DES < 12 months

RISK of postpolypectomy bleeding, if not stopping APA
Overall risk (no APA): 1,2%
Post-EMR bleeding: 3-7%
Risk ↑↑ Clopidogrel > 1 cm polyps

RISK of the lesion
Progression adenoma to invasive cancer is slow

Yes

Can treatment be postponed?

Interrupt clopidogrel ("cardiologist's responsibility")

Endoscopy under dual APA and prophylactic measures

ESGE *ESGE guidelines. Endoscopy 2011; 43:445-458*
Guideline update 2015

Snare polypectomy and APA - proposals for 2015

- 1- Don't use pure cutting current mode (*high evidence/strong recommendation*)
- 2- Stop thienopyridines (*moderate evidence, strong recommendation*)
- 3- Continue low dose of aspirin, irrespective of polyp size or method of resection. (*high evidence/strong recommendation*)
- 4- Use at least one prophylactic endoscopic technique (*high evidence, strong recommendation*)

EMR and APA - proposals for 2015

1. Use a microprocessor controlled current, no pure cutting (*high evidence/strong recommendation*)
2. Stop low dose aspirin for large lesions (> 1 cm) (*moderate evidence, weak recommendation*)
3. Stop thienopyridines (*low evidence, weak recommendation*)
4. Prophylactically close the EMR defect as much as possible using endoclips (*moderate evidence, weak recommendation*)

Case – endoscopic polypectomy large polyps

- Cardiologist advice “agree for temporary interruption of clopidogrel”
- ASA continued / stop clopidogrel 7 days before
- January 2015: EMR resection of both adenomas (submucosal injection of 5 ml of an adrenalin solution 1:20 000)
- Visible vessel after EMR – oozing bleeding

